Fortress Biotech (FBIO) to Release Earnings on Thursday

Fortress Biotech (NASDAQ:FBIO) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $16.30 million for the quarter.

Fortress Biotech Trading Up 1.7 %

NASDAQ:FBIO opened at $1.75 on Wednesday. Fortress Biotech has a 12 month low of $1.36 and a 12 month high of $2.89. The firm has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $1.78. The stock has a market capitalization of $48.31 million, a price-to-earnings ratio of -0.57 and a beta of 1.75.

Analyst Upgrades and Downgrades

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $16.00 target price (up from $15.00) on shares of Fortress Biotech in a report on Tuesday, March 11th.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.